Depression severity and sleep efficiency's associations with amyloid burden are additive but dependent on underlying genetic risk in late life depression.
Anita Shankar, Maria Kryza-Lacombe, Philip S Insel, Edith Harris, Michelle T Kassel, Lizabeth Goldstein, Andrew D Krystal, Susan M Landau, Duygu Tosun, Meryl A Butters, Paul Aisen, Rema Raman, Arthur W Toga, Clifford R Jack, J Craig Nelson, R Scott Mackin
{"title":"Depression severity and sleep efficiency's associations with amyloid burden are additive but dependent on underlying genetic risk in late life depression.","authors":"Anita Shankar, Maria Kryza-Lacombe, Philip S Insel, Edith Harris, Michelle T Kassel, Lizabeth Goldstein, Andrew D Krystal, Susan M Landau, Duygu Tosun, Meryl A Butters, Paul Aisen, Rema Raman, Arthur W Toga, Clifford R Jack, J Craig Nelson, R Scott Mackin","doi":"10.1002/dad2.70478","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Evidence linking late-life depression (LLD) to amyloid beta (Aβ) burden remains mixed, possibly in part due to limited examinations of the confounding role of comorbid sleep disturbance and the moderating role of the apolipoprotein E (<i>APOE</i>) ɛ4 gene.</p><p><strong>Methods: </strong>We analyzed 110 older adults (ages 65-88, 66% female) with LLD to jointly model depression severity and sleep disturbance's relationship with Aβ, and to examine the moderating role of <i>APOE</i> ɛ4 genotype.</p><p><strong>Results: </strong>Depression severity, sleep efficiency, and sleep duration did not demonstrate a direct relationship with Aβ; however, a significant <i>APOE</i> ɛ4 moderation effect occurred for depression severity and sleep efficiency. In <i>APOE</i> ɛ4 carriers only, higher depression severity and lower sleep efficiency were associated with greater total Aβ burden and indicated greater likelihood of reaching clinical cutoffs for amyloid positivity. The effects of depressive symptoms and sleep efficiency were statistically unique and additive. Exploratory analyses demonstrated <i>APOE</i> ɛ4 also moderated the effect of lifetime duration of untreated depression on increased Aβ.</p><p><strong>Discussion: </strong>Depression severity and sleep efficiency's relationship with Aβ may be dependent on the presence of the <i>APOE</i> ɛ4 allele. This, among other individual differences, may partially explain mixed findings examining LLD as a risk factor for Alzheimer's disease. Furthermore, these findings do not suggest that the relationship between depression severity and amyloid is explained by the confounding role of sleep duration or sleep efficiency.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 4","pages":"e70478"},"PeriodicalIF":4.4000,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650511/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/dad2.70478","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/10/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Evidence linking late-life depression (LLD) to amyloid beta (Aβ) burden remains mixed, possibly in part due to limited examinations of the confounding role of comorbid sleep disturbance and the moderating role of the apolipoprotein E (APOE) ɛ4 gene.
Methods: We analyzed 110 older adults (ages 65-88, 66% female) with LLD to jointly model depression severity and sleep disturbance's relationship with Aβ, and to examine the moderating role of APOE ɛ4 genotype.
Results: Depression severity, sleep efficiency, and sleep duration did not demonstrate a direct relationship with Aβ; however, a significant APOE ɛ4 moderation effect occurred for depression severity and sleep efficiency. In APOE ɛ4 carriers only, higher depression severity and lower sleep efficiency were associated with greater total Aβ burden and indicated greater likelihood of reaching clinical cutoffs for amyloid positivity. The effects of depressive symptoms and sleep efficiency were statistically unique and additive. Exploratory analyses demonstrated APOE ɛ4 also moderated the effect of lifetime duration of untreated depression on increased Aβ.
Discussion: Depression severity and sleep efficiency's relationship with Aβ may be dependent on the presence of the APOE ɛ4 allele. This, among other individual differences, may partially explain mixed findings examining LLD as a risk factor for Alzheimer's disease. Furthermore, these findings do not suggest that the relationship between depression severity and amyloid is explained by the confounding role of sleep duration or sleep efficiency.
期刊介绍:
Alzheimer''s & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) is an open access, peer-reviewed, journal from the Alzheimer''s Association® that will publish new research that reports the discovery, development and validation of instruments, technologies, algorithms, and innovative processes. Papers will cover a range of topics interested in the early and accurate detection of individuals with memory complaints and/or among asymptomatic individuals at elevated risk for various forms of memory disorders. The expectation for published papers will be to translate fundamental knowledge about the neurobiology of the disease into practical reports that describe both the conceptual and methodological aspects of the submitted scientific inquiry. Published topics will explore the development of biomarkers, surrogate markers, and conceptual/methodological challenges. Publication priority will be given to papers that 1) describe putative surrogate markers that accurately track disease progression, 2) biomarkers that fulfill international regulatory requirements, 3) reports from large, well-characterized population-based cohorts that comprise the heterogeneity and diversity of asymptomatic individuals and 4) algorithmic development that considers multi-marker arrays (e.g., integrated-omics, genetics, biofluids, imaging, etc.) and advanced computational analytics and technologies.